OKYO vs. PBYI, CTNM, RAPT, TNGX, TARA, KRRO, ACTU, LYEL, GLSI, and IKT
Should you be buying OKYO Pharma stock or one of its competitors? The main competitors of OKYO Pharma include Puma Biotechnology (PBYI), Contineum Therapeutics (CTNM), RAPT Therapeutics (RAPT), Tango Therapeutics (TNGX), Protara Therapeutics (TARA), Korro Bio (KRRO), Actuate Therapeutics (ACTU), Lyell Immunopharma (LYEL), Greenwich LifeSciences (GLSI), and Inhibikase Therapeutics (IKT). These companies are all part of the "pharmaceutical products" industry.
OKYO Pharma vs.
OKYO Pharma (NASDAQ:OKYO) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, community ranking, valuation and profitability.
Puma Biotechnology has a net margin of 9.56% compared to OKYO Pharma's net margin of 0.00%. Puma Biotechnology's return on equity of 41.60% beat OKYO Pharma's return on equity.
Puma Biotechnology received 544 more outperform votes than OKYO Pharma when rated by MarketBeat users. However, 100.00% of users gave OKYO Pharma an outperform vote while only 67.23% of users gave Puma Biotechnology an outperform vote.
3.0% of OKYO Pharma shares are owned by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are owned by institutional investors. 40.5% of OKYO Pharma shares are owned by insiders. Comparatively, 23.7% of Puma Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
OKYO Pharma currently has a consensus price target of $7.00, indicating a potential upside of 545.16%. Puma Biotechnology has a consensus price target of $7.00, indicating a potential upside of 149.55%. Given OKYO Pharma's higher possible upside, equities research analysts plainly believe OKYO Pharma is more favorable than Puma Biotechnology.
In the previous week, OKYO Pharma had 2 more articles in the media than Puma Biotechnology. MarketBeat recorded 3 mentions for OKYO Pharma and 1 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 1.89 beat OKYO Pharma's score of 0.96 indicating that Puma Biotechnology is being referred to more favorably in the news media.
OKYO Pharma has a beta of -0.32, meaning that its stock price is 132% less volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500.
Puma Biotechnology has higher revenue and earnings than OKYO Pharma.
Summary
Puma Biotechnology beats OKYO Pharma on 9 of the 13 factors compared between the two stocks.
Get OKYO Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for OKYO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OKYO Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:OKYO) was last updated on 4/12/2025 by MarketBeat.com Staff
Buy OKYO Stock Free OKYO Stock Alerts